Stock Events

Stock Events

Prothena 

$8.88
56
+$0.02+0.23% 20:00 Today
+$0.00+0%20:01After hours

Statistics

Day High
9.08
Day Low
8.73
52W High
11.8
52W Low
7.73
Volume
353,117
Avg. Volume
562,995
Mkt Cap
455.87M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-2.34
-1.36
-0.38
0.6
Expected EPS
-0.21
Actual EPS
N/A

Financials

-2,520.57%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
9.68MRevenue
-244.09MNet Income

Analyst Ratings

16.00Average Price Target
The highest estimate is 20.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRTA. It's not an investment recommendation.
Apple
10
AAPL
NVIDIA
10
NVDA
Tesla
9
TSLA
Microsoft
8
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap31B
Biogen is a biotech firm that competes with Prothena in the neurodegenerative diseases space, particularly in developing therapies for Alzheimer's disease.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly is a pharmaceutical company that competes with Prothena in the development of treatments for diseases like Alzheimer's, sharing a focus on neurodegenerative disorders.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG competes in the neurodegenerative disease market, particularly in Alzheimer's and Parkinson's disease treatments, areas of focus for Prothena.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie competes with Prothena in researching therapies for neurological disorders, including Alzheimer's and Parkinson's diseases.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is involved in developing treatments for serious neurological diseases, competing with Prothena in the neurodegenerative disease research field.
Pfizer
PFE
Mkt Cap152.69B
Pfizer is a global pharmaceutical company that has initiatives in neurodegenerative diseases, making it a competitor to Prothena in the Alzheimer's and Parkinson's disease areas.
Novartis
NVS
Mkt Cap286.78B
Novartis AG competes with Prothena in the development of novel therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. is involved in the development of treatments for Alzheimer's disease, directly competing with Prothena's focus on neurodegenerative disorders.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals, Inc. competes with Prothena in developing RNA-targeted therapies for diseases, including neurodegenerative disorders.

About

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Show more...
CEO
Gene G. Kinney
Employees
67
Country
Ireland
ISIN
IE00B91XRN20
WKN
000A1KAVV

Listings

STU
DE
0PT.STU
LSE
GB
0Y3M.LSE
MU
DE
0PT.MU
F
DE
0PT.F

0 Comments

Share your thoughts

FAQ

What is Prothena stock price today?▼
The current price of PRTA is $8.88 USD — it has increased by +0.23% in the past 24 hours. Watch Prothena stock price performance more closely on the chart.
What is Prothena stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Prothena stocks are traded under the ticker PRTA.
Is Prothena stock price growing?▼
PRTA stock has fallen by -2.63% compared to the previous week, the month change is a +2.54% rise, over the last year Prothena has showed a +7.64% increase.
What is Prothena market cap?▼
Today Prothena has the market capitalization of 455.87M
When is the next Prothena earnings date?▼
Prothena is going to release the next earnings report on October 29, 2026.
What were Prothena earnings last quarter?▼
PRTA earnings for the last quarter are -0.36 USD per share, whereas the estimation was -0.39 USD resulting in a +7.69% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Prothena revenue for the last year?▼
Prothena revenue for the last year amounts to 9.68M USD.
What is Prothena net income for the last year?▼
PRTA net income for the last year is -244.09M USD.
How many employees does Prothena have?▼
As of August 17, 2026, the company has 67 employees.
In which sector is Prothena located?▼
Prothena operates in the Health & Wellness sector.
When did Prothena complete a stock split?▼
Prothena has not had any recent stock splits.
Where is Prothena headquartered?▼
Prothena is headquartered in DUBLIN 2, Ireland.